New drug trial aims to soothe painful pouchitis

NCT ID NCT06864403

Recruiting now Disease control Sponsor: University of North Carolina, Chapel Hill Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether mirikizumab (Omvoh) can reduce symptoms of chronic pouchitis, a condition where the internal pouch created after colon surgery becomes inflamed. Twenty-five adults will receive the drug every four weeks for a year. Researchers will track symptom changes using a standard scoring system.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mirikizumab (Omvoh)
What this could lead to: If it works, this could offer a new treatment option for people with chronic pouchitis, reducing symptoms and improving quality of life.
What could go wrong: This is a small, early-phase study with only 25 participants, so results may not apply to everyone. The drug may not work as hoped, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POUCH, ILEAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ileal neoplasm pouchitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POUCH, ILEAL POUCHES, ILEOANAL POUCHITIS

Contacts and locations

Locations

Allegheny Health Network
NOT_YET_RECRUITING

Pittsburgh, Pennsylvania, 15212, United States
Mayo Clinic
RECRUITING

Rochester, Minnesota, 55905, United States
NYU Langone Health
RECRUITING

New York, New York, 10016, United States
UCLA Vatche & Tamar Manoukian Division of Digestive Diseases
RECRUITING

Los Angeles, California, 90024, United States
University of North Carolina
RECRUITING

Chapel Hill, North Carolina, 27599-7080, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.